Updated guidelines support even lower cholesterol levels for at-risk patients.
Deborah
D
Levenson
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000097:blood / Q000592:standards*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000517:prevention & control*; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000517:prevention & control; D009203:Myocardial Infarction / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D017035:Pravastatin / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D012307:Risk Factors; D040242:Risk Reduction Behavior; D019821:Simvastatin / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood; D014481:United States
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D014280:Triglycerides; D019821:Simvastatin; D017035:Pravastatin